The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.

[1]  N. McNaughton,et al.  Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study , 2020, Journal of psychopharmacology.

[2]  Y. Ning,et al.  Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. , 2019, Journal of affective disorders.

[3]  D. Greenstein,et al.  Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. , 2019, Journal of affective disorders.

[4]  Xiang Li,et al.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. , 2019, JAMA psychiatry.

[5]  R. Temple,et al.  Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class. , 2019, The New England journal of medicine.

[6]  J. Talbot,et al.  Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. , 2019, The American journal of psychiatry.

[7]  M. Fava,et al.  Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression , 2018, Depression and anxiety.

[8]  D. M. Lyons,et al.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. , 2018, The American journal of psychiatry.

[9]  P. Cuijpers,et al.  Are studies of psychotherapies for depression more or less generalizable than studies of antidepressants? , 2018, Journal of affective disorders.

[10]  M. Olfson,et al.  Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression , 2018, Journal of managed care & specialty pharmacy.

[11]  L. Davidson,et al.  Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. , 2018, Journal of affective disorders.

[12]  J. Mann,et al.  Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. , 2017, The American journal of psychiatry.

[13]  Kelly C. Lee,et al.  Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. , 2017, Journal of affective disorders.

[14]  E. Ballard,et al.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.

[15]  T. Suppes,et al.  Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. , 2017, The Journal of clinical psychiatry.

[16]  C. Zorumski,et al.  Use of Ketamine in Clinical Practice: A Time for Optimism and Caution. , 2017, JAMA psychiatry.

[17]  M. Frye,et al.  A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders , 2017, JAMA psychiatry.

[18]  L. Bartova,et al.  Administration of ketamine for unipolar and bipolar depression , 2017, International journal of psychiatry in clinical practice.

[19]  Daniel J. Müller,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder , 2016, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[20]  C. Nemeroff,et al.  WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN? , 2016, Depression and anxiety.

[21]  E. Brown,et al.  Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. , 2016, The Journal of clinical psychiatry.

[22]  R. Shelton,et al.  A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.

[23]  R. McIntyre,et al.  A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect , 2016, Journal of clinical psychopharmacology.

[24]  D. Luckenbaugh,et al.  A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. , 2015, Bipolar disorders.

[25]  M. Frye,et al.  Concomitant Benzodiazepine Use Attenuates Ketamine Response: Implications for Large Scale Study Design and Clinical Development , 2015, Journal of clinical psychopharmacology.

[26]  K. Laws,et al.  The use of ketamine as an antidepressant: a systematic review and meta‐analysis , 2015, Human psychopharmacology.

[27]  R. Lam,et al.  Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions , 2014, CNS Drugs.

[28]  Dennis S. Charney,et al.  Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression , 2013, Biological Psychiatry.

[29]  Paul A. Harris,et al.  Procurement of shared data instruments for Research Electronic Data Capture (REDCap) , 2013, J. Biomed. Informatics.

[30]  F. Zitman,et al.  Efficacy versus Effectiveness: A Direct Comparison of the Outcome of Treatment for Mild to Moderate Depression in Randomized Controlled Trials and Daily Practice , 2012, Psychotherapy and Psychosomatics.

[31]  H. Möller,et al.  Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. , 2010, The Journal of clinical psychiatry.

[32]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[33]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[34]  M. Gitlin.  Treatment-resistant bipolar disorder , 2006, Molecular Psychiatry.

[35]  M. Fava,et al.  Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D , 2004, Psychological Medicine.

[36]  J. Markowitz,et al.  The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression , 2003, Biological Psychiatry.

[37]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[38]  A. Rush,et al.  When at first you don't succeed: sequential strategies for antidepressant nonresponders. , 1997, The Journal of clinical psychiatry.

[39]  C. Loo,et al.  Side-effects associated with ketamine use in depression: a systematic review. , 2018, The lancet. Psychiatry.

[40]  S. Southwick,et al.  Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) , 1998, Journal of traumatic stress.